Glutamate antagonists limit tumor growth
AUTOR(ES)
Rzeski, Wojciech
FONTE
The National Academy of Sciences
RESUMO
Neuronal progenitors and tumor cells possess propensity to proliferate and to migrate. Glutamate regulates proliferation and migration of neurons during development, but it is not known whether it influences proliferation and migration of tumor cells. We demonstrate that glutamate antagonists inhibit proliferation of human tumor cells. Colon adenocarcinoma, astrocytoma, and breast and lung carcinoma cells were most sensitive to the antiproliferative effect of the N-methyl-d-aspartate antagonist dizocilpine, whereas breast and lung carcinoma, colon adenocarcinoma, and neuroblastoma cells responded most favorably to the α-amino-3-hydroxy-5-methyl-4-isoxazole-propionate antagonist GYKI52466. The antiproliferative effect of glutamate antagonists was Ca2+ dependent and resulted from decreased cell division and increased cell death. Morphological alterations induced by glutamate antagonists in tumor cells consisted of reduced membrane ruffling and pseudopodial protrusions. Furthermore, glutamate antagonists decreased motility and invasive growth of tumor cells. These findings suggest anticancer potential of glutamate antagonists.
ACESSO AO ARTIGO
http://www.pubmedcentral.nih.gov/articlerender.fcgi?artid=33475Documentos Relacionados
- Angiogenin antagonists prevent tumor growth in vivo.
- Glutamate antagonists: Deadly liaisons with cancer
- Diazepam dependence prevented by glutamate antagonists.
- Inhibition of growth of human mammary tumor cells by potent antagonists of luteinizing hormone-releasing hormone.
- TGF-β antagonists: Why suppress a tumor suppressor?